JAK Inhibitors vs. Antibodies: Current Strategies and Future Frontiers in Autoimmune Disease

The JAK-STAT Signaling Pathway in Immunity and Autoimmune Diseases

The JAK–STAT signaling pathway serves as a central conduit for signaling by numerous cytokines and interferons, playing a critical role in hematopoietic cell differentiation, immune homeostasis, and the development of select inflammatory and neoplastic disorders. Dysregulated JAK–STAT signaling underlies a range of autoimmune diseases, hematologic malignancies, and chronic inflammatory conditions, making this pathway an important therapeutic target^[2].

The activation of the classic JAK-STAT signaling pathway mainly involves the following five steps^[3].
I Ligand binding: The ligand (e.g., cytokines or growth factors) binds to its corresponding receptor on the cell surface, inducing receptor dimerization and recruitment of associated JAKs.

II Activation of JAKs: JAKs are constitutively bound to the cytoplasmic domain of the receptor. When the ligand binds to the receptor, JAKs undergo transphosphorylation, leading to tyrosine phosphorylation of the receptor and creation of docking sites for STAT proteins.

III STAT phosphorylation: Activated JAKs phosphorylate tyrosine residues on the receptor, forming a structure called "phosphotyrosine residue". This structure can be recognized by the SH2 domains of STAT proteins, which are then phosphorylated by JAKs.

IV STAT activation and dimerization: Phosphorylated STATs detach from the receptor and form homodimers or heterodimers via reciprocal SH2-phosphotyrosine interactions.

V Transcriptional activation: STAT dimers translocate into the nucleus, where they bind to specific DNA sequences and modulate the transcription of target genes.

To maintain signaling fidelity and prevent excessive activation, several negative regulators such as protein inhibitor of activated STAT (PIAS), suppressor of cytokine signaling (SOCS)/cytokine-inducible SH2-containing protein (CIS) family members, and protein tyrosine phosphatases (PTPs) are engaged: PIAS inhibits STAT-DNA binding; CIS/SOCS proteins prevent STAT recruitment to the receptor, inhibit JAK activity, or target JAK/STAT for degradation; and PTPs—such as CD45—dephosphorylate STAT dimers, JAKs, or receptor subunits (Fig. 1).

The JAK-STAT signaling pathway serves as a critical conduit for cytokine-mediated immune regulation, orchestrating the differentiation, development, and function of multiple immune cell subsets.

Distinct cytokines activate specific STAT proteins, thereby guiding lineage decisions and effector programs. For example, IL-12 activates STAT4 to promote Th1 differentiation, which contributes to pro-inflammatory responses in autoimmune conditions such as rheumatoid arthritis (RA) and psoriasis. IL-4 signals via STAT6 to induce Th2 responses, often implicated in allergic diseases like atopic dermatitis (AD). IL-6 and IL-23 activate STAT3 to drive Th17 cell differentiation and IL-17 production, key mediators in chronic tissue inflammation. Conversely, IL-2 signaling through STAT5 supports the development of regulatory T cells (Tregs), promoting immune tolerance and homeostasis.

Together, these cytokines tightly regulate the differentiation and function of immune cells, contributing to the development of either protective immune responses or chronic inflammatory diseases.

Clinical Applications of JAK Inhibitors and Cytokine-Targeted Antibodies

The JAK-STAT signaling pathway plays a central role in the pathogenesis of both autoimmune diseases and cancer. Therapeutic modulation of this pathway has demonstrated the ability to suppress tumor growth, metastasis, and angiogenesis in oncology, while also reducing inflammation and aberrant immune activation in autoimmune conditions. Various treatment strategies have been developed, including JAK inhibitors, cytokine- or receptor-targeting antibodies, STAT inhibitors, and emerging modalities such as peptide-based agents, oligonucleotides, and small interfering RNAs (siRNAs).

Among the diverse strategies targeting the JAK-STAT pathway, JAK inhibitors and cytokine-targeted antibodies have emerged as the most clinically validated and widely adopted modalities. They both aim to modulate dysregulated cytokine signaling to restore immune homeostasis, but they differ significantly in their mechanisms of action, molecular characteristics, and other key aspects. A comparative overview is presented in Table 1.

In summary, JAK inhibitors and cytokine-targeted antibodies represent two distinct approaches to JAK-STAT pathway modulation. In the following sections, we will delve into their clinical applications in detail and highlight emerging trends shaping the future of autoimmune disease treatment.

JAK inhibitors have shown significant efficacy across a range of inflammatory autoimmune diseases, including RA, psoriasis, psoriatic arthritis (PsA), and inflammatory bowel disease (IBD). The following table presents a partial overview of the clinical progress of key JAK inhibitors.

JAK inhibitors have shown considerable therapeutic potential in treating inflammatory autoimmune diseases. First-generation pan-JAK inhibitors, including Tofacitinib, Baricitinib, and Ruxolitinib, are FDA-approved and widely used, but their non-selective inhibition may result in off-target effects and safety concerns. In response, second-generation inhibitors like Upadacitinib and Decernotinib have been developed with increased selectivity to improve safety profiles^[5]. However, enhanced selectivity may compromise efficacy. Current research efforts focus on developing highly selective JAK inhibitors, such as SHR0302, Abrocitinib, and Delgocitinib, to achieve an optimal balance between therapeutic efficacy and tolerability.

This figure demonstrates the distinct effects of selectively targeting different JAK isoforms (JAK1, JAK2, JAK3, and TYK2) on various cytokine signaling pathways. By selectively inhibiting specific JAK isoforms, it becomes possible to precisely modulate particular cytokine signals, thereby minimizing off-target effects and enhancing therapeutic efficacy. For example, selective inhibition of JAK3 can reduce the activity of cytokines such as IL-2 and IL-15, which are critical for immune cell activation, while preserving other pathways essential for normal hematopoiesis and immune homeostasis.

Cytokine-targeted antibodies have been extensively studied. For example, blockade of IL-2, IL-12, IL-17, and TNF has been successfully used to treat chronic inflammatory diseases such as RA, IBD, and psoriasis. Some of these blockades are market-approved, such as anti-IL-2Ralpha, anti-IL-5, anti-IL-6, anti-IL-6R, anti-IL-12, and anti-IL-23. The anti- IL-2Ralpha antibody, also known as daclizumab, markedly inhibited the phosphorylation of JAK1, JAK3, and STAT5a/b, thus significantly decreasing transplant rejection. Siltuximab is an IL-6 antagonist and has been approved for the treatment of idiopathic multicentric Castleman's disease (iMCD). Tocilizumab, an anti-IL-6R humanized antibody, has been approved for the treatment of RA, cytokine release syndrome (CRS), and iMCD^[6-8].

Cytokine-antibody fusion proteins represent an innovative biopharmaceutical class, enhancing the therapeutic index of cytokine payloads by fusing specific antibodies with cytokines or receptor antagonists. Examples include ch14.18-IL-2, Hu14.18-IL-2, NHS-IL2LT, DI-Leu16-IL-2, BC1-IL-12, and L19-TNF. These fusion proteins have proven effective in treating chronic inflammatory diseases like RA, IBD, and psoriasis by targeting cytokines such as IL-2, IL-12, IL-17, and TNF^[6-8].

The Future Landscape of Autoimmune Disease Treatment

The therapeutic target landscape for autoimmune diseases has evolved substantially since 2020. Between 2020 and 2024, the number of agents under investigation increased from 131 to 193, encompassing 92 distinct therapeutic targets^[1]. This growth reflects both continued development within established cytokine and kinase families—such as the IL family and JAK enzymes—and increased investment in emerging targets such as TL1A, OX40, and TYK2.

Notably, Figure 5 highlights the continued prominence of the JAK family—including JAK1, JAK2, JAK3, and the increasingly differentiated TYK2 isoform—as key intracellular kinase targets in autoimmune diseases. In parallel, cytokine-related targets maintain a dominant role, with expanded investigation into IL family members (e.g., IL-4, IL-5, IL-13) and TNF superfamily components such as TL1A, OX40, and CD40.

The immunology drug development pipeline remains highly dynamic, with several first-in-class therapies expected to reach the clinic in the coming years. Novel agents targeting the OX40/OX40L axis (e.g., rocatinlimab, amlitelimab) aim to address upstream regulators of IL-4/IL-13 production in dermatology. In chronic obstructive pulmonary disease (COPD), two competitive candidates targeting IL-33—itepekimab and the dual IL-33/ST2 inhibitor tozorakimab—represent an emerging therapeutic class. Additionally, modulation of the CD40/CD40L axis may offer new treatment options for systemic autoimmune diseases, including dazodalibep for Sjögren’s syndrome and dapirolizumab for lupus erythematosus. In gastrointestinal disorders, three TL1A-targeted candidates (tulisokibart, RVT-3101, duvakitug) are advancing clinical development in Crohn’s disease and UC.

First-in-class opportunities are also emerging for targets including IL-4, IL-33, IL-18, IRAK4 (enabling pan-IL-1 family inhibition), and TSLP (a key upstream mediator of type 2 inflammation). Combination approaches (e.g., IL-17/TNF co-targeting, dual kinase inhibitors) and innovations in selectivity (IL-17A/F isoforms), dosing regimens (long-acting IL-5 inhibitors), and delivery methods (oral IL-17 inhibitors) are poised to broaden therapeutic options.

Competition is intensifying for first-to-market positions (TL1A, OX40, TSLP, IL-33, TYK2) and best-in-class agents (e.g., enhanced-selectivity IL-23/JAK inhibitors), particularly for type 2 inflammatory disorders. The field is increasingly moving toward complementary strategies that leverage common inflammatory pathways while addressing disease-specific pathophysiology. Key challenges include optimizing drug positioning, applying biomarker-driven patient stratification, and balancing the roles of oral small molecules versus injectable biologics. These trends mirror oncology’s evolution and herald a new era in autoimmune disease management.